

## **Reviva to Participate in Upcoming Investor Conferences in May 2025**

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences.

### **Benchmark Healthcare House Call Virtual Investor Conference**

Format: Fireside chat and 1×1 investor meetings

Date: Thursday, May 29, 2025

Time: 11:15 a.m. ET

Location: Virtual

### **Lytham Partners Spring 2025 Investor Conference**

Format: Company presentation and 1×1 investor meetings

Date: Thursday, May 29, 2025

Time: 2:00 p.m. ET

Location: Virtual

Webcast Link: [Click Here](#)

To arrange a meeting with management please register for the event [Here](#)

### **About Reviva**

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

### **Corporate Contact:**

Reviva Pharmaceuticals Holdings, Inc.

Laxminarayan Bhat, PhD

[www.revivapharma.com](http://www.revivapharma.com)

### **Investor Relations Contact:**

LifeSci Advisors, LLC

Bruce Mackle

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)

